14 terminated. 14 Phase 2, 5 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 14 | Terminated 14 |
| Phase 1 | 5 | Terminated 5 |
Follow palbociclib: new trials by email Literature Review of palbociclib trials Research Report on palbociclib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc) NKT2152, palbociclib, sasanlimab - ccRCC, Clear Cell Renal Cell Carcinoma | Phase 2 | Terminated | NiKang Therapeutics, Inc. | 18 | 2023-07-28 | 2025-11-12 |
| Palbociclib + Ganitumab In Ewing Sarcoma Palbociclib, Ganitumab - Ewing Sarcoma, Ewing's Sarcoma Recurrent | Phase 2 | Terminated | Dana-Farber Cancer Institute | 10 | 2019-12-05 | 2024-08-01 |
| Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study Abemaciclib, Anastrozole, Fulvestrant - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma | Phase 2 | Terminated | M.D. Anderson Cancer Center | 4 | 2019-05-31 | 2024-12-27 |
| Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer Palbociclib 75mg, Letrozole 2.5mg, T-DM1 - HER2-positive Breast Cancer, Breast Cancer Metastatic | Phase 1 / Phase 2 | Terminated | University of Kansas Medical Center | 3 | 2018-10-15 | 2024-03-05 |
| Preoperative Palbociclib in Patients With DCIS of the Breast That Are Candidates for Surgery Palbociclib - DCIS | Phase 2 | Terminated | Georgetown University | 17 | 2018-10-08 | 2025-09-26 |
| Survival Prolongation by Rationale Innovative Genomics Avelumab, Axitinib, Palbociclib - Non-small Cell Lung Cancer Metastatic, Non-small Cell Lung Cancer Stage IIIB | Phase 1 / Phase 2 | Terminated | Worldwide Innovative Network Association | 15 | 2017-11-29 | 2023-12-18 |
| HR+/HER2- Advanced Breast Cancer and Endocrine Resistance Palbociclib, Fulvestrant, Capecitabine - Breast Cancer Metastatic | Phase 2 | Terminated | Theodoros Foukakis | 42 | 2017-10-24 | 2024-03-08 |
| Phase 1/2 Study of Amcenestrant (SAR439859) Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer Amcenestrant, Palbociclib, Alpelisib - Breast Cancer | Phase 1 / Phase 2 | Terminated | Sanofi | 136 | 2017-09-20 | 2025-11-24 |
| Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab in Stage II-III ER+ HER2+ Breast Cancer Palbociclib, Letrozole, Trastuzumab - Breast Cancer, Cancer of Breast | Phase 2 | Terminated | Washington University School of Medicine | 26 | 2017-06-30 | 2021-09-29 |
| Palbociclib in Treating Patients With Metastatic HER-2 Positive Breast Cancer With Brain Metastasis Cognitive Assessment, Palbociclib, Quality-of-Life Assessment - Breast Carcinoma Metastatic in the Brain, Estrogen Receptor Negative | Phase 2 | Terminated | Northwestern University | 12 | 2016-08-31 | 2020-04-14 |
| Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M) PF-06747775, Palbociclib, Avelumab - Non-Small Cell Lung Cancer | Phase 1 / Phase 2 | Terminated | Pfizer | 65 | 2015-05-14 | 2021-06-10 |
| Phase II Trial of Palbociclib in Patients With Metastatic Urothelial Cancer After Failure of First-Line Chemotherapy Palbociclib - Metastatic Urothelial Carcinoma (UC) | Phase 2 | Terminated | UNC Lineberger Comprehensive Cancer Center | 12 | 2015-03-17 | 2018-11-16 |
| A Study of GDC-0810 Single Agent or in Combination With Palbociclib and/or a Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer GDC-0810, LHRH Agonist, Palbociclib - Breast Cancer | Phase 1 / Phase 2 | Terminated | Genentech, Inc. | 152 | 2014-12-29 | 2021-06-18 |
| A Study of PD 0332991 in Patients With Recurrent Rb Positive Glioblastoma PD 0332991 (pre-surgery), PD 0332991, Resection as clinical care - Glioblastoma, Gliosarcoma | Phase 2 | Terminated | University of California, San Francisco | 23 | 2010-09-01 | 2015-07-17 |
Breast Neoplasms (6) · Carcinoma, Non-Small-Cell Lung (2) · Adenocarcinoma (1) · Astrocytoma (1) · Carcinoma (1) · Carcinoma, Intraductal, Noninfiltrating (1) · Carcinoma, Renal Cell (1) · Carcinoma, Transitional Cell (1) · Glioblastoma (1) · Glioma (1) · Gliosarcoma (1) · Kidney Diseases (1) · Kidney Neoplasms (1) · Neoplasms (1) · Neoplasms by Site (1)
Dana-Farber Cancer Institute (1) · Genentech, Inc. (1) · Georgetown University (1) · M.D. Anderson Cancer Center (1) · NiKang Therapeutics, Inc. (1) · Northwestern University (1) · Pfizer (1) · Sanofi (1) · Theodoros Foukakis (1) · UNC Lineberger Comprehensive Cancer Center (1) · University of California, San Francisco (1) · University of Kansas Medical Center (1) · Washington University School of Medicine (1) · Worldwide Innovative Network Association (1)
United States (13) · Spain (3) · South Korea (2) · United Kingdom (2) · Australia (1) · Belgium (1) · Canada (1) · Czechia (1) · France (1) · Israel (1) · Italy (1) · Japan (1) · Luxembourg (1) · Netherlands (1) · Poland (1)
Candace Mainor, MD (1) · Cristofanilli Massimo, MD (1) · David Shulman, MD (1) · Foluso O Ademuyiwa, M.D, MPH (1) · Lauren Nye, MD (1) · Matthew I Milowsky, MD (1) · Michael D Prados, MD (1) · Senthilkumar Damodaran, MD (1)
PMID 30151703, PMID 35307972, PMID 35840573, PMID 36401732, PMID 36609389, PMID 37306107, PMID 42649946
2017 (2), 2014 (1), 2016 (1), P30CA060553 (1)